Biotage AB (publ)
Biotage AB (publ) Fundamental Analysis
Biotage AB (publ) (BITGF) shows moderate financial fundamentals with a PE ratio of 54.66, profit margin of 14.28%, and ROE of 5.30%. The company generates $1.5B in annual revenue with strong year-over-year growth of 10.42%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BITGF's fundamental strength across five key dimensions:
Efficiency Score
WeakBITGF struggles to generate sufficient returns from assets.
Valuation Score
ModerateBITGF shows balanced valuation metrics.
Growth Score
ModerateBITGF shows steady but slowing expansion.
Financial Health Score
ExcellentBITGF maintains a strong and stable balance sheet.
Profitability Score
WeakBITGF struggles to sustain strong margins.
Key Financial Metrics
Is BITGF Expensive or Cheap?
P/E Ratio
BITGF trades at 54.66 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BITGF's PEG of -0.57 indicates potential undervaluation.
Price to Book
The market values Biotage AB (publ) at 2.96 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 32.00 times EBITDA. This signals the market has high growth expectations.
How Well Does BITGF Make Money?
Net Profit Margin
For every $100 in sales, Biotage AB (publ) keeps $14.28 as profit after all expenses.
Operating Margin
Core operations generate 15.65 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.30 in profit for every $100 of shareholder equity.
ROA
Biotage AB (publ) generates $4.42 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Biotage AB (publ) produces operating cash flow of $314.01M, showing steady but balanced cash generation.
Free Cash Flow
Biotage AB (publ) generates strong free cash flow of $197.01M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.46 in free cash annually.
FCF Yield
BITGF converts 1.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
54.66
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.57
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.96
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.80
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.06
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How BITGF Stacks Against Its Sector Peers
| Metric | BITGF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 54.66 | 28.25 | Worse (Expensive) |
| ROE | 5.30% | 780.00% | Weak |
| Net Margin | 14.28% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.06 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 2.53 | 4.66 | Strong Liquidity |
| ROA | 4.42% | -14687.00% (disorted) | Weak |
BITGF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Biotage AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
52.04%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
23.82%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
58.82%
Industry Style: Defensive, Growth, Innovation
High Growth